Cytotoxic Effects of Phosphonate-Functionalized Mesoporous Silica Nanoparticles
Source abstract
Abstract
In this work, we synthesized pristine mesoporous silica nanoparticles (MSN) and functionalized these with phosphonate groups (MSN-Phos). We report, for the first time, cell death in MCF-7 cells (human breast adenocarcinoma cell line) when exposed to the empty MSN and MSN-Phos nanoparticles. In comparison, the same nanoparticles were found to elicit few deleterious effects on normal human foreskin fibroblast cells (BJ cells). MCF-7 cells were found to exhibit a concentration-dependent uptake, whereas no detectable nanoparticle uptake was observed in the BJ cells, irrespective of treatment dosage. A disruption of the cell cycle in the MCF-7 cells was determined to be the cause of cell death from the nanoparticle exposure, thereby suggesting the role of nondrug loaded MSN and MSN-Phos as effective anticancer drugs.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Nanoparticles: synthesis and applications · Graphene and Nanomaterials Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Chemical and Biomolecular Engineering, National University of Singapore, 4 Engineering Drive 4, Singapore 117585, Singapore
Funding
Ministry of Education - Singapore
References (50)
Show source-provided references
1. 10.3322/caac.2125410.3322/caac.21254 ↗
2. 10.1126/science.121965710.1126/science.1219657 ↗
3. 10.1016/j.addr.2007.04.00810.1016/j.addr.2007.04.008 ↗
4. 10.1002/smll.20070000510.1002/smll.200700005 ↗
5. Fukuda M. · Oncology · 1999 · 13 · 77
6. 10.1016/j.actbio.2012.05.02210.1016/j.actbio.2012.05.022 ↗
7. 10.18632/oncotarget.104410.18632/oncotarget.1044 ↗
8. 10.1116/1.281569010.1116/1.2815690 ↗
9. 10.1039/C4NR02814G10.1039/C4NR02814G ↗
10. 10.1002/adma.20110471410.1002/adma.201104714 ↗
11. 10.2147/IJN.S3218810.2147/IJN.S32188 ↗
12. 10.1002/adma.20080139310.1002/adma.200801393 ↗
13. 10.1016/j.jfda.2014.01.01210.1016/j.jfda.2014.01.012 ↗
14. 10.1016/j.biomaterials.2013.12.08010.1016/j.biomaterials.2013.12.080 ↗
15. 10.1039/C5CS00499C10.1039/C5CS00499C ↗
16. 10.1021/acsnano.5b0648710.1021/acsnano.5b06487 ↗
17. 10.1002/adfm.20140166410.1002/adfm.201401664 ↗
18. 10.1039/b502142c10.1039/b502142c ↗
19. 10.1039/C4TX00210E10.1039/C4TX00210E ↗
20. 10.1016/j.biomaterials.2013.12.03310.1016/j.biomaterials.2013.12.033 ↗
21. 10.2217/nnm.14.1910.2217/nnm.14.19 ↗
22. 10.1039/c0jm03301d10.1039/c0jm03301d ↗
23. 10.1038/ncomms265510.1038/ncomms2655 ↗
24. 10.1016/j.biomaterials.2013.09.02410.1016/j.biomaterials.2013.09.024 ↗
25. 10.1002/adma.20140086610.1002/adma.201400866 ↗
26. 10.1016/j.actbio.2015.05.01010.1016/j.actbio.2015.05.010 ↗
27. 10.1016/j.biomaterials.2015.04.03410.1016/j.biomaterials.2015.04.034 ↗
28. 10.1039/C4CC07563C10.1039/C4CC07563C ↗
29. 10.1016/j.biomaterials.2013.02.01410.1016/j.biomaterials.2013.02.014 ↗
30. Wang X. · Int. J. Clin. Exp. Pathol. · 2014 · 7 · 1337
31. 10.1002/anie.20110153610.1002/anie.201101536 ↗
32. 10.1002/adhm.20120011610.1002/adhm.201200116 ↗
33. 10.1038/nrc187710.1038/nrc1877 ↗
34. 10.1016/j.jcis.2012.03.01410.1016/j.jcis.2012.03.014 ↗
35. 10.1002/adhm.20130032410.1002/adhm.201300324 ↗
36. Yang K. N. · Cancer Biol. Med. · 2014 · 11 · 34
37. 10.1016/j.ijpharm.2012.10.01110.1016/j.ijpharm.2012.10.011 ↗
38. 10.1021/tx300166u10.1021/tx300166u ↗
39. 10.1016/S1748-0132(08)70014-810.1016/S1748-0132(08)70014-8 ↗
40. 10.1002/ppsc.20130011110.1002/ppsc.201300111 ↗
41. 10.1021/es100417s10.1021/es100417s ↗
42. 10.1021/tx800289z10.1021/tx800289z ↗
43. 10.1016/j.biomaterials.2013.09.04310.1016/j.biomaterials.2013.09.043 ↗
44. 10.1002/adma.20110476310.1002/adma.201104763 ↗
45. 10.1038/nrc265710.1038/nrc2657 ↗
46. 10.1038/onc.2008.30710.1038/onc.2008.307 ↗
47. 10.1038/nri252610.1038/nri2526 ↗
48. 10.1038/sj.onc.120987310.1038/sj.onc.1209873 ↗
49. 10.1128/MCB.16.3.76210.1128/MCB.16.3.762 ↗
50. 10.1128/MCB.25.16.6937-6947.200510.1128/MCB.25.16.6937-6947.2005 ↗